Document is current

Documents that mention this clinical trial

Real-world survival outcomes with immune checkpoint inhibitors in large-cell neuroendocrine tumors of lung
https://doi.org/10.1136/jitc-2020-001999

Documents that mention this clinical trial

Real-world survival outcomes with immune checkpoint inhibitors in large-cell neuroendocrine tumors of lung
https://doi.org/10.1136/jitc-2020-001999

Documents that mention this clinical trial

Real-world survival outcomes with immune checkpoint inhibitors in large-cell neuroendocrine tumors of lung
https://doi.org/10.1136/jitc-2020-001999

Documents that mention this clinical trial

Real-world survival outcomes with immune checkpoint inhibitors in large-cell neuroendocrine tumors of lung
https://doi.org/10.1136/jitc-2020-001999

Documents that mention this clinical trial

Evaluation of immune checkpoint inhibitor efficacy for solid tumors with <i>CD274</i> (PD-L1 gene) amplification identified by comprehensive genomic profiling: retrospective study based on a nationwide database
https://doi.org/10.1136/jitc-2024-010130

DART/SWOG/NCI phase II anti-CTLA-4/PD-1 trial: clear cell carcinomas of ovary, endometrium, cervix
https://doi.org/10.1136/jitc-2025-012805

Outcomes of Patients With Rare Cancers Treated With Combination Immune Checkpoint Inhibitors With and Without Previous Anti–PD-1/L1 Exposure: National Cancer Institute/SWOG S1609
https://doi.org/10.1200/oa-25-00110

Update in the treatment of non-melanoma skin cancers: the use of PD-1 inhibitors in basal cell carcinoma and cutaneous squamous-cell carcinoma
https://doi.org/10.1136/jitc-2022-005082

Efficacy of pembrolizumab in patients with pituitary carcinoma: report of four cases from a phase II study
https://doi.org/10.1136/jitc-2020-001532

Evaluation of mixed response in tumor size and survival in patients with rare cancers treated with dual checkpoint inhibitor therapy (DART SWOG S1609)
https://doi.org/10.1136/jitc-2025-013260

A phase II basket trial of dual anti–CTLA-4 and anti–PD-1 blockade in rare tumors (DART) SWOG S1609: The vulvar cancers.
https://doi.org/10.1200/jco.2023.41.16_suppl.5517

Phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: the desmoid tumors
https://doi.org/10.1136/jitc-2024-009128

Phase II basket trial of Dual Anti-CTLA-4 and anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609: pancreatic neuroendocrine neoplasm (PNEN) cohort
https://doi.org/10.1136/jitc-2025-011760

Chemotherapy-free treatment of recurrent advanced ovarian cancer: myth or reality?
https://doi.org/10.1136/ijgc-2022-003719

Phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609: adrenocortical carcinoma cohort
https://doi.org/10.1136/jitc-2024-009074

A phase II basket trial of dual anti–CTLA-4 and anti–PD-1 blockade in rare tumors (DART SWOG 1609) in patients with refractory gallbladder cancer (cohort 48).
https://doi.org/10.1200/jco.2023.41.16_suppl.e16330

795 A multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)
https://doi.org/10.1136/jitc-2020-sitc2020.0795

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer
https://doi.org/10.1136/jitc-2022-006624

Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)
https://doi.org/10.1136/jitc-2021-002990

Chromatin remodeling (SWI/SNF) complexes, cancer, and response to immunotherapy
https://doi.org/10.1136/jitc-2022-004669

A phase II basket trial of dual anti–CTLA-4 and anti–PD-1 blockade in rare tumors (DART) SWOG S1609: The desmoid tumors (cohort 27).
https://doi.org/10.1200/jco.2023.41.16_suppl.11516

Metastatic myxopapillary ependymoma treated with immunotherapy achieving durable response
https://doi.org/10.1136/bcr-2020-236242

616 Correlations between baseline tumor burden and overall survival in patients with rare cancers treated with immune checkpoint inhibitors (NCI/SWOG S1609)
https://doi.org/10.1136/jitc-2024-sitc2024.0616

Real-world survival outcomes with immune checkpoint inhibitors in large-cell neuroendocrine tumors of lung
https://doi.org/10.1136/jitc-2020-001999